Panbela receives positive ema opinion on orphan designation for ivospemin (sbp-101) in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma

Minneapolis, dec. 14, 2022 (globe newswire) -- pa nbela therapeutics, inc. (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the european medicines agency (ema) committee for orphan medicinal products issued a positive opinion on panbela's application for orphan designation of ivospemin (sbp-101) in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (pda). previously, the u.s. food and drug administration (fda) granted orphan drug designation to sbp-101.
PBLA Ratings Summary
PBLA Quant Ranking